{
    "clinical_study": {
        "@rank": "153074", 
        "arm_group": [
            {
                "arm_group_label": "Formulation 1 Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 1 at a 21 day interval."
            }, 
            {
                "arm_group_label": "Formulation 2 Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 2 at a 21 day interval."
            }, 
            {
                "arm_group_label": "Formulation 3 Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 3 at a 21 day interval."
            }, 
            {
                "arm_group_label": "Formulation 4 Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 4 at a 21 day interval."
            }, 
            {
                "arm_group_label": "Placebo Group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects in this group will receive two doses of placebo at a 21 day interval."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this placebo controlled study is to evaluate the safety and immunogenicity of\n      different formulations of GSK Biologicals H7N1 influenza vaccine in subjects 65 years of age\n      and older. The study will evaluate safety related events and antibody immune responses to\n      different formulations of study vaccine."
        }, 
        "brief_title": "Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female adults who are 65 years of age and older at the time of first study\n             vaccination.\n\n          -  Written informed consent obtained from the subject.\n\n          -  Subjects who the investigator believes can and will comply with the requirements of\n             the protocol.\n\n          -  Stable health status, as established by medical history and physical exam, and\n             defined by absence of a health event satisfying the definition of a serious adverse\n             event, or a change in an ongoing drug therapy due to therapeutic failure or symptoms\n             of drug toxicity, within 1 month prior to enrollment.\n\n          -  Access to a consistent means of telephone contact, which may be either in the home or\n             at the workplace, land line or mobile, but NOT a pay phone or other multiple-user\n             device.\n\n        Exclusion Criteria:\n\n          -  Presence or evidence of neurological or psychiatric diagnoses which, although stable,\n             are deemed by the investigator to render the potential subject unable/unlikely to\n             provide accurate safety reports.\n\n          -  Presence or evidence of substance abuse.\n\n          -  Diagnosed with cancer, or treatment for cancer within three years.\n\n               -  Persons with a history of cancer who are disease-free without treatment for\n                  three years or more are eligible.\n\n               -  Persons with a history of histologically-confirmed basal cell carcinoma of the\n                  skin successfully treated with local excision only are excepted and are\n                  eligible, but other histologic types of skin cancer are exclusionary.\n\n               -  Women who are disease-free three years or more after treatment for breast cancer\n                  and receiving long-term prophylaxis are eligible.\n\n          -  Diagnosed with excessive daytime sleepiness (unintended sleep episodes during the day\n             present almost daily for at least one month), or narcolepsy; or history of narcolepsy\n             in subject's parent, sibling or child.\n\n          -  Presence of a temperature \u2265 38.0\u00baC (\u2265100.4\u00baF), or acute symptoms greater than \"mild\"\n             severity on the scheduled date of first vaccination.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition including\n             history of human immunodeficiency virus (HIV) infection.\n\n          -  Receipt of systemic glucocorticoids within 30 days prior to the first dose of study\n             vaccine/placebo, or any other cytotoxic, immunosuppressive or immune-modifying drugs\n             within 6 months of first study vaccine/placebo dose.  Topical, intra-articularly\n             injected, or inhaled glucocorticoids, topical calcineurin inhibitors or imiquimod are\n             allowed.\n\n          -  Any significant disorder of coagulation or treatment with warfarin derivatives or\n             heparin.  Persons receiving individual doses of low molecular weight heparin outside\n             of 24 hours prior to vaccination are eligible.  Persons receiving prophylactic\n             antiplatelet medications, e.g., low-dose aspirin, and without a clinically-apparent\n             bleeding tendency, are eligible.\n\n          -  An acute evolving neurological disorder or Guillain Barr\u00e9 Syndrome within 42 days of\n             receipt of prior seasonal or pandemic influenza vaccine.\n\n          -  Administration of an inactive vaccine within 14 days or of a live attenuated vaccine\n             within 30 days before the first dose of study vaccine/placebo.\n\n          -  Planned administration of any vaccine other than the study vaccine/placebo before\n             blood sampling at the Day 42 visit.\n\n          -  Previous administration of any H7 vaccine or physician-confirmed H7 disease.\n\n          -  Use of any investigational or non-registered product other than the study vaccine\n             within 30 days preceding the first dose of study vaccine/placebo, or planned use\n             during the study period.\n\n          -  Receipt of any immunoglobulins and/or any blood products within 90 days before the\n             first dose of study vaccine/placebo, or planned administration of any of these\n             products during the study period.\n\n          -  Any known or suspected allergy to any constituent of influenza vaccines or component\n             used in the manufacturing process of the study vaccine including a history of\n             anaphylactic-type reaction to consumption of eggs; or a history of severe adverse\n             reaction to a previous influenza vaccine.\n\n          -  Any condition which, in the opinion of the investigator, prevents the subject from\n             participating in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "367", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01949090", 
            "org_study_id": "200613"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Formulation 1 Group", 
                    "Formulation 4 Group", 
                    "Formulation 2 Group", 
                    "Formulation 3 Group"
                ], 
                "description": "Two doses of GSK2789869A H7N1 vaccine administered intramuscularly to the deltoid region at Day 0 and Day 21.", 
                "intervention_name": "Investigational H7N1 vaccine GSK2789869A", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo Group", 
                "description": "Two doses of GSK2789868A H7N1 vaccine administered intramuscularly to the deltoid region at Day 0 and Day 21.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "H7N1", 
            "AS03 adjuvant", 
            "Safety", 
            "Immunogenicity", 
            "Influenza", 
            "Adults", 
            "Elderly adults"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hollywood", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33024"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boise", 
                        "country": "United States", 
                        "state": "Idaho", 
                        "zip": "83642"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lenexa", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66219"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wichita", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "67207"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40509"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Truro", 
                        "country": "Canada", 
                        "state": "Nova Scotia", 
                        "zip": "B2N 1L2"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sudbury", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "P3E 1H5"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M9W 4L6"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "5", 
        "official_title": "An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A and GSK2789868A Administered in Adults 65 Years of Age and Older", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Biologics and Genetic Therapies Directorate (BGTD)", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The following aggregate variables will be calculated for each adjuvanted H7N1 vaccine group: \u2022 Seroconversion rates (SCR); \u2022 Seroprotection rates (SPR); \u2022  Mean Geometric Increase (MGI)", 
                "measure": "Humoral immune response in terms of vaccine-homologous hemagglutination inhibition (HI) antibody titers", 
                "safety_issue": "No", 
                "time_frame": "At Day 42"
            }, 
            {
                "description": "Occurrence of each solicited local symptom", 
                "measure": "Occurrence of adverse events (AEs) after each vaccination", 
                "safety_issue": "No", 
                "time_frame": "During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccination"
            }, 
            {
                "description": "Occurrence of each solicited general symptom", 
                "measure": "Occurrence of adverse events (AEs) after each vaccination", 
                "safety_issue": "No", 
                "time_frame": "During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccination"
            }, 
            {
                "description": "Occurrence of clinical safety laboratory abnormalities reported for samples", 
                "measure": "Occurrence of adverse events (AEs) after each vaccination", 
                "safety_issue": "No", 
                "time_frame": "At the Day 0, 7, 21, 28, and 42 visits"
            }, 
            {
                "description": "Occurrence of unsolicited adverse events", 
                "measure": "Occurrence of adverse events (AEs) after each vaccination", 
                "safety_issue": "No", 
                "time_frame": "21 days after each dose"
            }, 
            {
                "description": "Occurrence of Medically Attended Adverse Events (MAEs), potential Immune Mediated Diseases (pIMDs) and Serious Adverse Events (SAEs)", 
                "measure": "Occurrence of adverse events (AEs) after each vaccination", 
                "safety_issue": "No", 
                "time_frame": "From Day 0 until the Day 42 visit"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01949090"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The following aggregate variables will be calculated for each study group:\u2022 GMTs; \u2022 Seropositivity rates; \u2022 SCR; \u2022 SPR; \u2022 MGI.", 
                "measure": "Vaccine-homologous (H7N1) HI antibody titers", 
                "safety_issue": "No", 
                "time_frame": "\u2022 GMTs and Seropositivity rates at Days 0, 21, 42 and Months 6 and 12; \u2022 SCR and MGI at Day 21, 42 (Placebo group only)  and Months 6 and 12; \u2022 SPR at Days 0, 21, 42 (Placebo group only) and Months 6 and 12."
            }, 
            {
                "description": "The following aggregate variables will be calculated for a subset of subjects in each study group:\u2022 GMTs; \u2022 Seropositivity rates; \u2022 SCR; \u2022 SPR; \u2022 MGI.", 
                "measure": "Vaccine-heterologous (H7N9) HI antibody titers", 
                "safety_issue": "No", 
                "time_frame": "\u2022 GMTs and Seropositivity rates and SPR at Days 0, 21, 42 and Months 6 and 12; \u2022 SCR and MGI at Day 21, 42 and Months 6 and 12."
            }, 
            {
                "description": "The following parameters will be calculated for a subset of subjects in each study group: \u2022 GMTs; \u2022 Seropositivity rates; \u2022 Vaccine response rate (VRR).", 
                "measure": "Vaccine homologous (H7N1) and heterologous (H7N9) neutralizing (MN) antibody titers", 
                "safety_issue": "No", 
                "time_frame": "\u2022 GMTs and Seropositivity rates at Days 0, 21, 42 and Month 6; \u2022 VRR at Days 21, 42 and Month 6."
            }, 
            {
                "measure": "Occurrence of MAEs, pIMDs and SAEs", 
                "safety_issue": "No", 
                "time_frame": "After the Day 42 visit until the Month 12 visit."
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}